PMA device
WiSE® (Wireless Stimulation of the Endocardium Technology) CRT System
EBR Systems, Inc. · Leadless Cardiac Resynchronization Therapy (Crt) (SEG, Class III) · First FDA decision Apr 11, 2025, newest Jun 18, 2025Heart failure
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
6
Naming "WiSE CRT"
MAUDE reports
108
Brand "WiSE CRT", since 2015
PubMed studies
43
Mentioning "WiSE CRT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing WiSE® (Wireless Stimulation of the Endocardium Technology) CRT System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
P240028-S001 · Decided Jun 18, 2025 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Leadless Cardiac Resynchronization Therapy (CRT) (SEG) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy System (WiSE CRT)National analysisReview closedCAG-00471NUpdated Nov 18, 2026
- Cardiac Resynchronization Therapy (CRT)Local determinationIn effectL39080Palmetto GBAUpdated Oct 19, 2021
Clinical trials
Device studies on ClinicalTrials.gov that name "WiSE CRT", any status and sponsor, newest update first.
- Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade PatientsActive, not recruiting
EBR Systems, Inc.Not on our public-company list
NCT02922036 · 300 participants (planned) · Start Jan 17, 2018 · Primary completion Nov 2027
Device: WiSE System · For: Heart Failure
Sites: Huntsville, Alabama; La Jolla, California; Fort Lauderdale, Florida · 68 sites in all
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "WiSE CRT", and for the whole product code for context.
This brand
108 reports: 75 malfunction, 27 injury, 6 death
Whole product code SEG
113 reports: 76 malfunction, 29 injury, 8 death
Newest reports for this brand
- WiSE CRT SystemMalfunction
3013596742-2026-00071 · Received Oct 30, 2026 · Event dated Sep 29, 2026
Device type: Leadless Cardiac Resynchronization Therapy (Crt) (SEG)
Device problem as coded: Human-Device Interface Problem
Patient problem as coded: Unspecified Heart Problem
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "WiSE CRT"[tiab]. The summary above synthesizes these.
- Becoming wiser with WiSE-CRT.
Varma N · Heart Rhythm · 2023Editorial
- Left Ventricular Endocardial Pacing/Leadless Pacing.
Hanley A, Heist EK · Card Electrophysiol Clin · 2019Review
- Leadless Devices: the Future of Pacing.
Furman BW, Wang B, Sajja A, et al. · Curr Cardiol Rep · 2025Review
- WiSE CRT Is Beneficial for Heart Failure Patients as a Rescue Therapy: Evidence From a Meta-Analysis.
Cang J, Liu Y, Zhu D, et al. · Front Cardiovasc Med · 2022Systematic Review
- Completely Leadless Cardiac Resynchronization Defibrillator System.
Sidhu BS, Gould J, Porter B, et al. · JACC Clin Electrophysiol · 2020
- Cost-effectiveness analysis of leadless cardiac resynchronization therapy.
Wijesuriya N, Mehta V, Vere F, et al. · J Cardiovasc Electrophysiol · 2023Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- [Endocardial left ventricular pacing in 2025].
Seifert M, Georgi C, Jankowska P, et al. · Herzschrittmacherther Elektrophysiol · 2025English Abstract, Review
- Leadless Pacing: Where We Currently Stand and What the Future Holds.
Ibrahim R, Khoury A, El-Chami MF · Curr Cardiol Rep · 2022Review
- Nontransvenous Cardiovascular Implantable Electronic Device Technology-A Review for the Anesthesiologist.
Cody J, Graul T, Holliday S, et al. · J Cardiothorac Vasc Anesth · 2021Review
- Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure.
Singh JP, Rinaldi CA, Sanders P, et al. · JAMA Cardiol · 2024Multicenter Study, Randomized Controlled Trial
- Long-Term Outcome of the First Completely Leadless Cardiac Resynchronization Therapy in the United States.
Mehlhorn D, Patel S, Verghese D, et al. · JACC Case Rep · 2023Case Reports
- Guided implantation of a leadless left ventricular endocardial electrode and acoustic transmitter using computed tomography anatomy, dynamic perfusion and mechanics, and predicted activation pattern.
Sidhu BS, Lee AWC, Gould J, et al. · Heart Rhythm · 2023Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.